This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EpimAb/Kymab FIT-IG Bispecific Antibody Program
Description: EpimAb and Kymab are developing bispecific antibodies for immuno-oncology combining EpimAb's Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform with antibodies sourced from Kymab's Kymouse platform.
EpiMab and Kymab
In October 2016, EpiMab and Kymab announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. Kymab will have the development and commercialization rights to these bispecifics in all geographical regions outside of China, and, under the terms for the cross license agreement, EpimAb will have the rights for the Chinese market. Each party is eligible to receive milestone payments and royalties for development programs pursued by the other party.
Partners: EpimAb Biotherapeutics
EpimAb/Kymab FIT-IG Bispecific Antibody Program News
Additional information available to subscribers only: